{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:56:03Z","timestamp":1778824563624,"version":"3.51.4"},"reference-count":150,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.semarthrit.2013.08.004","type":"journal-article","created":{"date-parts":[[2013,9,27]],"date-time":"2013-09-27T23:16:33Z","timestamp":1380323793000},"page":"479-488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint"],"prefix":"10.1016","volume":"43","author":[{"given":"Maurizio","family":"Cutolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Kitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet L.C.M.","family":"van Riel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2013.08.004_bib1","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/rheumatology\/41.7.793","article-title":"The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century","volume":"41","author":"Symmons","year":"2002","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/art.23177","article-title":"Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I","volume":"58","author":"Helmick","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib3","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib4","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib5","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib7","doi-asserted-by":"crossref","first-page":"R160","DOI":"10.1186\/ar3900","article-title":"Anti-tumour necrosis factor \u03b1 therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis","volume":"14","author":"Stavropoulos-Kalinoglou","year":"2012","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib8","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1136\/ard.2006.060319","article-title":"Redefining overweight and obesity in rheumatoid arthritis patients","volume":"66","author":"Stavropoulos-Kalinoglou","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib9","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/HJR.0b013e3283271ceb","article-title":"Association of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis","volume":"16","author":"Metsios","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/ard.2009.115717","article-title":"Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: evidence for substantial undertreatment of lipid-associated cardiovascular risk?","volume":"69","author":"Toms","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib11","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/157016110791112269","article-title":"Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors","volume":"8","author":"Toms","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib12","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/rheumatology\/kem169","article-title":"Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis","volume":"46","author":"Panoulas","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib13","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1093\/rheumatology\/ken159","article-title":"Hypertension in rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/ard.2010.142133","article-title":"Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives","volume":"70","author":"Kitas","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ejim.2012.06.016","article-title":"Inflammatory arthritis as a novel risk factor for cardiovascular disease","volume":"23","author":"John","year":"2012","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib16","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1136\/annrheumdis-2012-201334","article-title":"How early in the course of rheumatoid arthritis does the excess cardiovascular risk appear?","volume":"71","author":"Kerola","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.semarthrit.2011.08.003","article-title":"Subclinical atherosclerosis and endothelial dysfunction in patients with early rheumatoid arthritis as evidenced by measurement of carotid intima-media thickness and flow-mediated vasodilation: an observational study","volume":"41","author":"Chatterjee Adhikari","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib18","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-010-1436-0","article-title":"Antibodies against oxidized low-density lipoprotein are associated with subclinical atherosclerosis in recent-onset rheumatoid arthritis","volume":"29","author":"Ahmed","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib19","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1093\/rheumatology\/ker275","article-title":"Vascular function and morphology in rheumatoid arthritis: a systematic review","volume":"50","author":"Sandoo","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7861\/clinmedicine.1-1-18","article-title":"Cardiac involvement in rheumatoid disease","volume":"1","author":"Kitas","year":"2001","journal-title":"Clin Med"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib21","article-title":"Heart involvement in rheumatoid arthritis: systematic review and meta-analysis","author":"Corrao","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1136\/ard.2010.143396","article-title":"The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study","volume":"70","author":"Lindhardsen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib23","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/ATVBAHA.109.190108","article-title":"Atherosclerosis in rheumatoid arthritis versus diabetes: a comparative study","volume":"29","author":"Stamatelopoulos","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib24","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1136\/annrheumdis-2011-201278","article-title":"Subclinical femoral atheromatosis in rheumatoid arthritis: comparable prevalence to diabetes mellitus in a case-controlled study","volume":"71","author":"Protogerou","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/HCO.0b013e32834703b5","article-title":"Rheumatoid arthritis: is it a coronary heart disease equivalent?","volume":"26","author":"John","year":"2011","journal-title":"Curr Opin Cardiol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib26","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.amjcard.2012.03.044","article-title":"Usefulness of risk scores to estimate the risk of cardiovascular disease in patients with rheumatoid arthritis","volume":"110","author":"Crowson","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib27","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/BOR.0b013e32834ff2fd","article-title":"Risk factors for cardiovascular disease in rheumatoid arthritis","volume":"24","author":"Gabriel","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib28","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib29","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.3899\/jrheum.100979","article-title":"The influence of rheumatoid arthritis disease characteristics on heart failure","volume":"38","author":"Myasoedova","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib30","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib31","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/1759720X11436239","article-title":"Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity","volume":"4","author":"Marks","year":"2012","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib32","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/acr.20371","article-title":"Systematic review and meta-analysis: anti-tumor necrosis factor \u03b1 therapy and cardiovascular events in rheumatoid arthritis","volume":"63","author":"Barnabe","year":"2011","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib33","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/rheumatology\/keq316","article-title":"Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systemic literature review","volume":"50","author":"Westlake","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib34","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib35","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1002\/art.22809","article-title":"Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor \u03b1 therapy: results from the British Society for Rheumatology Biologics Register","volume":"56","author":"Dixon","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.trsl.2010.09.005","article-title":"Tumor necrosis factor-\u03b1 blockade, cardiovascular outcomes, and survival in rheumatoid arthritis","volume":"157","author":"Al-Aly","year":"2011","journal-title":"Transl Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib37","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/ard.2009.124180","article-title":"Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial","volume":"69","author":"Klarenbeek","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/jhh.2011.36","article-title":"Anti-TNF\u03b1 therapy may lead to blood pressure reductions through improved endothelium-dependent microvascular function in patients with rheumatoid arthritis","volume":"25","author":"Sandoo","year":"2011","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib39","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","article-title":"Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib40","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/rheumatology\/kem291","article-title":"Blockage of tumor necrosis factor-\u03b1 in rheumatoid arthritis: effects on components of rheumatoid cachexia","volume":"46","author":"Metsios","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib41","doi-asserted-by":"crossref","first-page":"R110","DOI":"10.1186\/ar2765","article-title":"Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60\u2014more than just an anti-inflammatory effect? A cross sectional study","volume":"11","author":"Toms","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib42","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1186\/ar2578","article-title":"Lack of association between glucocorticoid use and presence of the metabolic syndrome in patients with rheumatoid arthritis: a cross-sectional study","volume":"10","author":"Toms","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib43","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2174\/138161212799504759","article-title":"Adverse cardiovascular effects of antirheumatic drugs: implications for clinical practice and research","volume":"18","author":"Gasparyan","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib44","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1002\/art.22117","article-title":"Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis","volume":"54","author":"van Staa","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib45","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/RHU.0b013e3181a5679d","article-title":"Factors influencing fracture risk, T score, and management of osteoporosis in patients with rheumatoid arthritis in the Consortium of Rheumatology Researchers of North America (CORRONA) registry","volume":"15","author":"Coulson","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib46","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/archinte.166.22.2495","article-title":"High-sensitivity C-reactive protein and risk of nontraumatic fractures in the Bruneck study","volume":"166","author":"Schett","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib47","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/jama.296.11.1353","article-title":"High-sensitivity C-reactive protein and fracture risk in elderly women","volume":"296","author":"Pasco","year":"2006","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib48","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.autrev.2013.03.015","article-title":"Biologic therapies and systemic bone loss in rheumatoid arthritis","volume":"12","author":"Dimitroulas","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib49","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-010-1462-4","article-title":"Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis","volume":"22","author":"Confavreux","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib50","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1136\/ard.2008.091264","article-title":"Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study","volume":"68","author":"Hoff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib51","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2012-202538","article-title":"Further emergent evidence for the vitamin D endocrine system involvement in autoimmune rheumatic disease risk and prognosis","volume":"72","author":"Cutolo","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib52","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/art.22350","article-title":"Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement","volume":"55","author":"Solomon","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib53","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/qjmed\/hcm126","article-title":"Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology","volume":"101","author":"Wall","year":"2008","journal-title":"QJM"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib54","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/RHU.0b013e31819b65bd","article-title":"Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice","volume":"15","author":"Ledwich","year":"2009","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib55","first-page":"1513","article-title":"Comparison of pulmonary abnormalities on high-resolution computed tomography in patients with early versus longstanding rheumatoid arthritis","volume":"35","author":"Mori","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib56","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1002\/art.27405","article-title":"Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study","volume":"62","author":"Bongartz","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib57","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.berh.2007.06.002","article-title":"Comorbidities in rheumatoid arthritis","volume":"21","author":"Michaud","year":"2007","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib58","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/03009740601153774","article-title":"Rheumatoid arthritis treatment and the risk of severe interstitial lung disease","volume":"36","author":"Wolfe","year":"2007","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib59","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib60","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2710.2010.01234.x","article-title":"Etanercept for the treatment of patients with rheumatoid arthritis and concurrent interstitial lung disease","volume":"37","author":"Horai","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib61","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/MCP.0b013e3283483ea5","article-title":"Biologic treatments and connective tissue disease associated interstitial lung disease","volume":"17","author":"Panopoulos","year":"2011","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/art.21758","article-title":"Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia","volume":"54","author":"Atkins","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.berh.2011.10.009","article-title":"Co-morbidities in established rheumatoid arthritis","volume":"25","author":"Gullick","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib64","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1136\/ard.2005.043877","article-title":"Morphological and quantitative assessment of mast cells in rheumatoid arthritis associated non-specific interstitial pneumonia and usual interstitial pneumonia","volume":"65","author":"Atkins","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib65","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.20765","article-title":"Increased CD4+ T cell infiltrates in rheumatoid arthritis-associated interstitial pneumonitis compared with idiopathic interstitial pneumonitis","volume":"52","author":"Turesson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib66","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/art.10524","article-title":"Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib67","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib68","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.3399\/bjgp09X472629","article-title":"Identification of new risk factors for pneumonia: population-based case-control study","volume":"59","author":"Vinogradova","year":"2009","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib69","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/acr.21812","article-title":"Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis","volume":"65","author":"Widdifield","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib70","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib71","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/annrheumdis-2011-200702","article-title":"Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis","volume":"71","author":"Dixon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib72","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib73","doi-asserted-by":"crossref","unstructured":"Singh JA, Wells GA, Christensen R, Tanjong-Ghogomu E, Maxwell L, Macdonald JK, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011 Feb 16;(2):CD008794","DOI":"10.1002\/14651858.CD008794"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infection during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib75","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/ard.2008.089276","article-title":"Association of methotrexate and tumour necrosis factor antagonists with risk of serious infectious outcomes including opportunistic infections in the CORRONA registry","volume":"69","author":"Greenberg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib76","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/rheumatology\/keq242","volume":"50","author":"Galloway","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib77","doi-asserted-by":"crossref","unstructured":"van Dartel SAA, Fransen J, Kievit W, Flendrie M, den Broeder AA, Visser H, et al. Difference in risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Ann Rheum Dis 2013;72:895-900","DOI":"10.1136\/annrheumdis-2012-201338"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib78","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib79","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib80","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib81","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/ard.2004.030528","article-title":"Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas","volume":"64","author":"Geborek","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.autrev.2009.07.006","article-title":"Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry","volume":"9","author":"Pallavicini","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib83","first-page":"2130","article-title":"Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors","volume":"32","author":"Chakravarty","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib84","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/rheumatology\/ker113","article-title":"Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis","volume":"50","author":"Amari","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib85","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1002\/art.22864","article-title":"Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib86","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/annrheumdis-2011-200622","article-title":"The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register","volume":"71","author":"Mercer","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib87","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1136\/ard.2008.097527","article-title":"Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment","volume":"68","author":"Simon","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib88","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Emery P, Bingham III CO, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 2010;37:558-67","DOI":"10.3899\/jrheum.090856"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib89","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib90","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/11531980-000000000-00000","article-title":"Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity","volume":"70","author":"Strand","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib91","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people","volume":"7","author":"Salaffi","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib92","first-page":"231","article-title":"Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response","volume":"8","author":"Kosinski","year":"2002","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib93","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1136\/ard.2008.102509","article-title":"Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission","volume":"69","author":"Kekow","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib94","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/art.20159","article-title":"Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate","volume":"50","author":"Maini","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib95","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1093\/rheumatology\/kel066","article-title":"Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicenter randomized clinical trial","volume":"45","author":"Westhovens","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib96","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1136\/ard.2010.143586","article-title":"Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial","volume":"70","author":"Strand","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib97","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib98","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/acr.21619","article-title":"Comparative responsiveness of the EuroQol-5D and Short Form 6D to improvement in patients with rheumatoid arthritis treated with tumor necrosis factor blockers: results of the Dutch Rheumatoid Arthritis Monitoring registry","volume":"64","author":"Buitinga","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib99","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/art.21450","article-title":"Patients\u2019 perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored","volume":"53","author":"Hewlett","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib100","first-page":"639","article-title":"Comparison of self-reported fatigue in rheumatoid arthritis and controls","volume":"22","author":"Belza","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib101","first-page":"1496","article-title":"Psychosocial variables and fatigue: a longitudinal study comparing individuals with rheumatoid arthritis and healthy controls","volume":"33","author":"Mancuso","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib102","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1080\/13548500701796931","article-title":"Predictors of fatigue over 1 year among people with rheumatoid arthritis","volume":"13","author":"Treharne","year":"2008","journal-title":"Psychol Health Med"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib103","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/rheumatology\/keq043","article-title":"Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis","volume":"49","author":"Van Hoogmoed","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib104","first-page":"24","article-title":"Anemia versus disease activity as cause of fatigue in rheumatoid arthritis","volume":"35","author":"Escobar","year":"2010","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/msc.124","article-title":"Measuring fatigue among women with Sj\u00f6gren\u2019s syndrome or rheumatoid arthritis: a comparison of the Profile of Fatigue (ProF) and the Multidimensional Fatigue Inventory (MFI)","volume":"6","author":"Goodchild","year":"2008","journal-title":"Musculoskeletal Care"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib106","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib107","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10067-011-1887-y","article-title":"The impact of disease activity, pain, disability and treatments on fatigue in established rheumatoid arthritis","volume":"31","author":"Campbell","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib108","first-page":"838","article-title":"Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis","volume":"25","author":"Yount","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib109","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/rheumatology\/ker162","article-title":"Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis","volume":"51","author":"Chauffier","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib110","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.pmrj.2010.03.026","article-title":"Fatigue in systemic lupus erythematosus and rheumatoid arthritis","volume":"2","author":"Ramsey-Goldman","year":"2010","journal-title":"PM R"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kep367","article-title":"A comparison of fatigue correlates in rheumatoid arthritis and osteoarthritis: disparity in associations with disability, anxiety and sleep disturbance","volume":"49","author":"Stebbings","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib112","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/1359105305051416","article-title":"Well-being in rheumatoid arthritis: the effects of disease duration and psychological factors","volume":"10","author":"Treharne","year":"2005","journal-title":"J Health Psychol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib113","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/rheumatology\/kel231","article-title":"Depression in rheumatoid arthritis\u2014underscoring the problem","volume":"45","author":"Sheehy","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib114","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/ard.2005.043158","article-title":"Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register","volume":"65","author":"Hyrich","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s11920-008-0042-1","article-title":"Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications","volume":"10","author":"Bruce","year":"2008","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib116","first-page":"1013","article-title":"Comorbid depression is an independent risk factor for mortality in patients with rheumatoid arthritis","volume":"32","author":"Ang","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib117","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1093\/rheumatology\/keh441","article-title":"Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients","volume":"44","author":"Treharne","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib118","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.genhosppsych.2009.04.001","article-title":"Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis","volume":"31","author":"Scherrer","year":"2009","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib119","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/acr.21689","article-title":"Correlates and predictors of disability in vulnerable US Hispanics with rheumatoid arthritis","volume":"64","author":"Karpouzas","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib120","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/03009740500343260","article-title":"Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms","volume":"35","author":"Rupp","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib121","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1749-6632.1999.tb07666.x","article-title":"Rheumatoid arthritis, personality, stress response style, and coping with illness. A preliminary survey","volume":"876","author":"Marcenaro","year":"1999","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib122","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/rheumatology\/38.11.1050","article-title":"Stress system response and rheumatoid arthritis: a multilevel approach","volume":"38","author":"Walker","year":"1999","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib123","first-page":"1095","article-title":"High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis","volume":"31","author":"Dessein","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib124","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.biopsycho.2009.02.003","article-title":"Association between C-reactive protein and depressive symptoms in women with rheumatoid arthritis","volume":"81","author":"Low","year":"2009","journal-title":"Biol Psychol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib125","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/art.24647","article-title":"Depression, inflammation, and pain in patients with rheumatoid arthritis","volume":"61","author":"Kojima","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib126","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pnpbp.2004.11.003","article-title":"Cytokines and major depression","volume":"29","author":"Schiepers","year":"2005","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib127","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbi.2010.10.008","article-title":"Immune suppression and immune activation in depression","volume":"25","author":"Blume","year":"2011","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib128","first-page":"457","article-title":"Immune activation and depression in women with rheumatoid arthritis","volume":"31","author":"Zautra","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib129","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1358\/mf.2004.26.5.831324","article-title":"Cognitive impairment in rheumatoid arthritis","volume":"26","author":"Appenzeller","year":"2004","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib130","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1002\/acr.21683","article-title":"Cognitive impairment in persons with rheumatoid arthritis","volume":"64","author":"Shin","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib131","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/acr.21814","article-title":"The relationship between perceived cognitive dysfunction and objective neuropsychological performance in persons with rheumatoid arthritis","volume":"65","author":"Shin","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib132","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0304-3959(01)00457-2","article-title":"The relationship of pain and depression to cognitive function in rheumatoid arthritis patients","volume":"96","author":"Brown","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib133","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10067-011-1795-1","article-title":"Assessment of biocorrelates for brain involvement in female patients with rheumatoid arthritis","volume":"31","author":"Hamed","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib134","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3233\/JAD-2012-111736","article-title":"Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: a population-based study","volume":"31","author":"Wallin","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib135","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jbspin.2010.01.017","article-title":"Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis","volume":"77","author":"Chen","year":"2010","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib136","first-page":"1006","article-title":"Work limitations among working persons with rheumatoid arthritis: results, reliability, and validity of the work limitations questionnaire in 836 patients","volume":"32","author":"Walker","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib137","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/rheumatology\/39.12.1403","article-title":"The impact of rheumatoid arthritis on employment status in the early years of disease: a UK community-based study","volume":"39","author":"Barrett","year":"2000","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib138","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/ard.61.4.335","article-title":"Which patients stop working because of rheumatoid arthritis? Results of five years\u2019 follow up in 732 patients from the Early RA Study (ERAS)","volume":"61","author":"Young","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib139","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/03009740510018633","article-title":"Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register","volume":"34","author":"Odeg\u00e5rd","year":"2005","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib140","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib141","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/art.20716","article-title":"Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial","volume":"52","author":"Puolakka","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib142","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1002\/art.11285","article-title":"Association between etanercept use and employment outcomes among patients with rheumatoid arthritis","volume":"48","author":"Yelin","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib143","first-page":"206","article-title":"Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (A) on work activity for patients with early RA","volume":"35","author":"Kimel","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib144","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1002\/art.24828","article-title":"Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis","volume":"61","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib145","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1136\/ard.2005.048439","article-title":"Work disability in early rheumatoid arthritis: higher rates but better clinical status in Finland compared with the US","volume":"65","author":"Chung","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib146","first-page":"1182","article-title":"Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis","volume":"30","author":"Osiri","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib147","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/ard.2010.148031","article-title":"Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis","volume":"70","author":"Marder","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib148","first-page":"666","article-title":"Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab [abstract]","volume":"71","author":"Gnanasakthy","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib149","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/annrheumdis-2012-eular.582","article-title":"Improvements in health-related quality of life (HRQOL) in patients with rheumatoid arthritis (RA) receiving secukinumab: results of a dose-finding study [abstract]","volume":"71","author":"Strand","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2013.08.004_bib150","doi-asserted-by":"crossref","first-page":"20059","DOI":"10.1074\/jbc.R700016200","article-title":"JAK-STAT signaling: from interferons to cytokines","volume":"282","author":"Schindler","year":"2007","journal-title":"J Biol Chem"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213001716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017213001716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T16:55:55Z","timestamp":1758732955000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017213001716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":150,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S0049017213001716"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2013.08.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2013.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}